Diaceutics plc AIM:DXRX
- Incorporated
- United Kingdom
- Chief executive
- Ryan Keeling
- Employees
- 208
- Reports in
- GBP
- Companies House
- NI055207
Read straight from the annual reports
193p at close on 5 Oct 2026 · 10 reported years, 2016–2025
| Line | FY201612/16 | FY201712/17 | FY201812/18 | FY201912/19 | FY202012/20 | FY202112/21 | FY202212/22 | FY202312/23 | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Gross profit | |||||||||||
| Operating profit | |||||||||||
| Adjusted operating profit | — | — | — | — | |||||||
| Exceptional items | — | — | — | — | |||||||
| Net finance cost | |||||||||||
| Profit before tax | |||||||||||
| Adjusted profit before tax | — | — | — | — | — | — | — | — | |||
| Tax charge | |||||||||||
| Profit for the year | |||||||||||
| EBITDA | |||||||||||
| Adjusted minus statutory PBT | — | — | — | — | — | — | — | — | |||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Adjusted EPS | — | — | — | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
10 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Annual Recurring Revenue (ARR) from DXRX platform/data subscriptions
ARR grew 19% to £19,958,000 (28% to £26.9m in USD); platform-based recurring contracts increasingly underpin revenue
page 21PMx integrated commercialization partnerships
First PMx agreement expanded in March 2025 to total contract value £13.0m through Sept 2028; second multi-year PMx deal signed in Q4 2025 worth £5.5m total, contributing £1.7m ARR; pipeline of 24 potential PMx customers, 8 already spending
page 16Additional expensed data costs in non-precision-medicine disease areas (~£2.0m)
Gross margin compressed to 82% (2024: 88%) due to additional expensed data costs related to data acquired in new, non-precision-medicine addressable market growth areas
page 23Shift to high-margin recurring revenue and platform scalability/operating leverage
Adjusted EBITDA margin rose to 20% (2024: 13%); EBITDA margin rose to 15% (2024: 7%); management expects continued leverage as revenue scales
page 212025 marked a significant milestone for Diaceutics. Against a backdrop of heightened budget discipline across pharma and biotech, we delivered strong revenue growth, returned the business to profitability, and continued to scale our platform globally. Trading year-to-date has remained positive, with Q1 2026 performing in line with the Board's expectations.
page 6On April 16, 2026, the Group agreed a variation to its existing 10-year lease (entered October 2021) for its Belfast office premises with landlord O'Connor & McCann Limited (a related party), extending the lease by a further five years (new expiry August 2036) and increasing annual rent from £195,000 to £235,000 from August 2026; treated as a non-adjusting event, so no adjustment made to the FY2025 financial statements
page 69No dividends were paid during 2025 and the Directors do not recommend payment of a dividend (2024: also no dividend; 2024 loss of £1,703,000).
page 68Directors adopted the going concern basis after considering financial performance and scenario plans to December 31, 2028, concluding adequate resources exist including at the lower end of sensitivity scenarios. Independent auditor Ernst & Young (senior statutory auditor Roger Wallace, Dublin) issued an unmodified/unqualified opinion that the financial statements give a true and fair view; sole key audit matter was revenue recognition (2025 revenue £38.4m); Group materiality was £384,370 (1% of Group revenue); no material uncertainties relating to going concern were identified for the period to December 31, 2028.
page 71- Sales: decrease in volume/value of the sales pipeline, velocity/conversion to contracted revenue, and/or reduction in contracted order book, driven by poor customer service, product performance, competition, loss of a major customer, macroeconomic conditions in biopharma, industry regulation changes or shifting commercial modelsp.42
- Human capital: restricted access to, retention of, or productivity of required skilled employees, including recruitment challenges, inadequate retention frameworks and misalignment of employee/company purposep.43
- Data & platform: restricted availability or disrupted continuity of the DXRX platform and/or its data supply chains, including loss of IP, loss of major data suppliers, or disruption/damage to platform, data or systemsp.43
- Laws & regulations: non-compliance with internal policies and external laws/regulations including data privacy laws (HIPAA, GDPR), industry/ethical regulations (Anti-Kickback Statute, Sunshine Act) and pharma commercial standardsp.44
Read from C000369-AR-2025-ch.
8 annual reports read, FY2018 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (8)
FY2026Next report expected 20 May 2027